3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Leukemia, Prolymphocytic, B-Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia, Myeloid, Acute
2
Stomach Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lymphoma, T-Cell
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Prolymphocytic, T-Cell
1
Leukemia, Myeloid
1
Leukemia, Large Granular Lymphocytic
1
Immunoblastic Lymphadenopathy
1
Enteropathy-Associated T-Cell Lymphoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
venetoclax
3
Cytarabine
3
zosuquidar trihydrochloride
2
Immunotherapy, Adoptive
2
ponatinib
1
gilteritinib
1
fludarabine phosphate
1
fludarabine
1
enasidenib
1
blinatumomab
1
asciminib
1
Sensitivity and Specificity
1
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
1
Idarubicin
1
Gemtuzumab
1
Filgrastim
1
Daunorubicin
1
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
1
2-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Leukemia, Myeloid
×
Sensitivity and Specificity
×
Clear all
NCT01864902
2016-01-28
CART33
Chinese PLA General Hospital
Phase 1/2
Unknown
10 enrolled